Boston, Massachusetts, 02115, United States
NCT Number: NCT01829191
Controlling Myopia Progression With Soft Contact Lenses (Contact Lens Control)
This study is to investigate whether novel soft contact lens optical designs can slow myopia progression
Looking for future studies?
Notify MeKey information
Conditions
Age range
8 year–12 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- The subject must be between 8 and 12 years of age.
- At least one of the subject's parents or legal guardian must read and understand English or Chinese.
- The subject's manifest objective refraction (measured with an auto refractor) must be sphere: between -0.25D and -4.50D, and cylinder: <1.50D in each eye.
- The subject's best sphere contact lens correction must lie between -0.75D (better of the two eyes)and -4.25D (poorer of the two eyes).
- The subject's cycloplegic objective refraction must be here: between -0.75D and -4.00D cylinder: < or equal to 1.00D in each eye.
- The subject must have 1.00D or less difference in spherical equivalent between the two eyes with cycloplegic refraction.
- The subject must have a spectacle lens best-corrected visual acuity of 0.8 (20/25) or better in both eyes.
- The subject's parent or legal guardian must read and sign the STAEMENT OF INFORMED CONSENT and the subject must read and sign the Child's Assent Form and be provided a copy of each form.
- The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
Exclusion criteria
- Ocular or systemic allergies or diseases that may interfere with contact lens wear.
- Systemic disease or autoimmune disease or use of medications (e.g. antihistamine), which may interfere with contact lens wear.
- Clinically significant (grade 3 or 4) corneal edema, corneal vascularization, corneal staining, or any other abnormality of the cornea, which may contraindicate contact lens wear.
- Clinically significant (grade 3 or 4) tarsal abnormalities or bulbar injection that might interfere with contact lens wear.
- Any ocular infection.
- Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
- Any infectious disease (e.g. hepatitis, tuberculosis) or an immunosuppressive disease (e.g. HIV)
- Diabetes
- Anisometropia of greater than 1.00D by cycloplegic refraction.
- Astigmatism of greater than 1.00D in either eye by cycloplegic refraction.
- Eye injury or surgery within eight weeks immediately prior to enrollment for this study.
- Previous refractive surgery, orthokeratology, keratoconus, or other corneal irregularity in either eye. Rigid contact lens wearers cannot be enrolled in the study unless they are off rigid contact lenses for at least 4 weeks.
- Strabismus in either eye.
- Pupil or lid abnormality or infection in either eye
- Central corneal scar in either eye
- Aphakia in either eye
- Contraindications to contact lens wear such as dry eye or history of prior unsuccessful contact lens wear.
- History of participation in prior clinical trials aimed to control myopia progression.
- Surgically altered eyes, ocular infection of any type, ocular inflammation.
- An anterior chamber angle grade 2 or narrower by the Van Herrick method
Treatment and study plan
Soft Contact Test Lens A
DeviceFDA-approved, non-marketed daily disposable soft contact lens, conventional design
Soft Contact Test Lens C
DeviceDaily disposable soft contact lens with new optical design
Primary outcomes
-
Spherical Equivalent Refractive Error
Time frame: Baseline and every 6 months post-baseline for 2 years
Cycloplegic spherical equivalent auto refraction of the subject's right eye was computed from the sphero-cylindrical refraction measured with an open-field auto refractor. The median of 3 repeated measures, each of which was the average of 3 consecutive readings, was used for the analysis. Higher values in spherical refraction indicate progression in Myopia.
Secondary outcomes
-
Axial Length
Time frame: Baseline and every 6 months for 2 years
Axial length was measured with the IOLMaster at baseline and every 6 months for 2 years. Five measurements were collected for each visit from the subject's right eye and the average of the five measurements was used for the analysis.
Sponsors and collaborators
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Registry information
Official study title
Controlling Myopia Progression With Soft Contact Lenses
Important dates
- Study start
- 2008
- Primary completion
- 2010
- Study completion
- 2010
- First posted
- Apr 11, 2013
- Registry last updated
- Jun 19, 2018
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Low-Dose Atropine for Treatment of Myopia
NCT03334253
Eye Diseases, Myopia
Birmingham, Alabama, United States
View Trial DetailsPatient Reported Outcomes With WaveLight Plus LASIK
NCT07087665
Eye Diseases, Myopia
Saint Louis Park, Minnesota, United States
View Trial DetailsMeasuring Outcomes of LASIK and EVO-ICL in Matched Populations
NCT06700460
Eye Diseases, Myopia
Omaha, Nebraska, United States
View Trial DetailsCorrection of Myopia Evaluation Trial 2
NCT00320593
Eye Diseases, Myopia
Birmingham, Alabama, United States
View Trial Details